Evidence map›Paper›PMID 30621774›Full record

ArticleParasites & vectors2019

Effect of flubendazole on developing stages of Loa loa in vitro and in vivo: a new approach for screening filaricidal agents.

Fanny Fri Fombad, Abdel Jelil Njouendou, Patrick Chounna Ndongmo, Manuel Ritter, Valerine C Chunda, Haelly M Metuge, Narcisse Victor T Gandjui, Peter Enyong, Flobert Njiokou, Achim Hoerauf and 2 more

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Comparative development of human filariaeFrontiers in tropical diseases · 2024
    Article
  3. Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023
    Article
  4. Article
  5. Host genetic backgrounds: the key to determining parasite-host adaptation.Frontiers in cellular and infection microbiology · 2023
    Review
  6. Review
  7. Advances in preclinical platforms ofFrontiers in tropical diseases · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Dataset onData in brief · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 4 countries.

Fanny Fri FombadParasites and Vectors Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
Abdel Jelil NjouendouParasites and Vectors Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
Patrick Chounna NdongmoParasites and Vectors Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
Manuel RitterInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany.
Valerine C ChundaParasites and Vectors Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
Haelly M MetugeParasites and Vectors Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
Narcisse Victor T GandjuiParasites and Vectors Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
Peter EnyongParasites and Vectors Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
Flobert NjiokouDepartment of Animal Biology and Physiology, Faculty of Science, University of Yaounde I, Yaounde, Cameroon.
Achim HoeraufInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany.
Charles D MackenzieDepartment of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI, 48824, USA.
Samuel WanjiParasites and Vectors Biology Research Unit (PAVBRU), Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon. samwandji@gmail.com.ORCID http://orcid.org/0000-0003-0022-8366
University of Buea · CMUniversity Hospital Bonn · DELiverpool School of Tropical Medicine · GBUniversité de Yaoundé I · CM

Funding

BMGF through DNDi, Geneva ID OPP1119042
6 · The paper itself

Abstract

backgroundLoiasis, an often-neglected tropical disease, is a threat to the success of lymphatic filariasis and onchocerciasis elimination programmes in rainforest areas of the central and western Africa. Its control and even its elimination might be possible through the use of a safe macrofilaricide, a prophylactic drug, or perhaps a vaccine. This present study evaluated the effect of flubendazole (FLBZ) on the development of Loa loa L3 in vitro and in vivo.

methodsInfective stages of L. loa were isolated and co-cultured in Dulbecco's Modified Eagle's Medium in the presence of monkey kidney epithelial cells (LLC-MK2) feeder cells. FLBZ and its principal metabolites, reduced flubendazole (RFLBZ) and hydrolyzed flubendazole (HFLBZ), were screened in vitro at concentrations 0.05, 0.1, 0.5, 1 and 10 μg/ml. The viability of the parasites was assessed microscopically daily for 15 days. For in vivo study, a total of 48 CcR3 KO mice were infected subcutaneously with 200 L. loa L3 and treated with 10 mg/kg FLBZ once daily for 5 consecutive days. Twenty-four animals were used as control and received L3 and vehicle. They were dissected at 5, 10, 15 and 20 days post-treatment for worm recovery.

resultsThe motility of L3 larvae in vitro was reduced from the second day of incubation with drugs at in vivo plasma concentration levels, with a strong correlation found between reduced motility and increased drug concentration (Spearman's rho = -0.9, P < 0.0001). Except for HFLBZ (0.05 μg/ml and 0.01 μg/ml), all concentrations of FLBZ, HFLBZ and RFLBZ interrupted the moulting of L. loa infective larvae to L4. In vivo, regardless of the experimental group, there was a decrease in parasite recovery with time. However, at each time point this reduction was more pronounced in the group of animals treated with FLBZ compared to equivalent control. Parasites were recovered from the flubendazole-treated groups only on day 5 post-inoculation at an average rate of 2.1%, a value significantly lower (Mann-Whitney U-test, U = 28, P = 0.0156) than the average of 31.1% recovered from the control group.

conclusionsThis study reveals the ability of flubendazole to inhibit the development of L. loa L3 both in vitro and in vivo, and in addition validates the importance of in vitro and animal models of L. loa as tools for the development of drugs against loiasis.

Indexed as

Africa, CentralAfrica, WesternAnimalsCell LineElephantiasis, FilarialFilaricidesHydrolysisLarvaLife Cycle StagesLoaLoiasisMebendazoleMiceMice, Inbred BALB CMice, KnockoutMovementFilaricidesflubendazoleMebendazoleFlubendazoleIn vitroIn vivoLoa loa L3MotilityMoulting

Identifiers

PMID30621774
PMCPMC6323797
OpenAlexW2910583238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.